New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:07 EDTIRWD, FRXIronwood receives NOA for patent expected to extend LINZESS patent protection
Ironwood Pharmaceuticals (IRWD) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of using LINZESS to treat patients with irritable bowel syndrome with constipation or chronic idiopathic constipation. The patent application, co-owned by Ironwood and Forest Laboratories (FRX), is expected to issue in mid-2014 and extend LINZESS patent protection into 2031. LINZESS is approved and marketed in the United States for the treatment of adult patients suffering from IBS-C or CIC. It is the first and only guanylate cyclase-C agonist approved by the FDA.
News For IRWD;FRX From The Last 14 Days
Check below for free stories on IRWD;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
10:32 EDTIRWDHigh option volume stocks
High option volume stocks: BXR IRWD ACM CECO TCK JAH MNST AVB EDU DAR
August 14, 2014
17:32 EDTFRXIcahn Associates gives quarterly update on stakes
NEW STAKES: Gannett (GCI). INCREASED STAKES: Navistar (NAV), eBay (EBAY), and Icahn Enterprises (IEP). DECREASED STAKES: Netflix (NFLX). LIQUIDATED STAKES: Forest Laboratories (FRX).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use